Wissenschaftliche Arbeiten

Prof. Dr. Mahmut Emre Yıldırım

52 Publikationen. Neben jeder Publikation steht die Quelle der Angabe.

Zurück zum Profil

  1. Real-world practices in RAS wild-type metastatic colorectal cancer patients treated with targeted agents in the first-line a nationwide onco-colon Turkey registry

    Anadolu Kliniği Tıp Bilimleri Dergisi, 2026

    DOI 10.21673/anadoluklin.1675424 Frei zugänglicher VolltextQuelle: OpenAlex

  2. Expression and prognostic importance of lymphocyte activation gene 3 and CD73 in advanced or metastatic hepatocellular carcinoma

    Journal of International Medical Research, 2026

    DOI 10.1177/03000605251386599 PMID 41521150 Frei zugänglicher VolltextQuelle: OpenAlex

  3. Clinical Characteristics, Treatment Patterns, and Survival Outcomes of Right-Sided RAS/RAF Wild-Type Metastatic Colorectal Cancer: A Real-World Multicenter Cohort Study

    Clinics and Practice, 2026

    DOI 10.3390/clinpract16090158 PMID 42783081 Frei zugänglicher VolltextQuelle: OpenAlex

  4. Real-World Survival Outcomes Following Metastasectomy in RAS Wild-Type mCRC: Insights from a Multicentre National Cohort Study

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15020467 PMID 41598406 Frei zugänglicher VolltextQuelle: ORCID

  5. Prognostic Value of the Cancer Inflammation Prognostic Index (CIPI) in De Novo Metastatic Colon Cancer: A Multicenter Retrospective Cohort Study

    Cancer Control, 2026

    DOI 10.1177/10732748261432273 PMID 41779425 Frei zugänglicher VolltextQuelle: ORCID

  6. Prognostic Factors in Advanced Bladder Cancer: A Real-World Retrospective Analysis

    Haydarpaşa Numune medical journal (Online), 2026

    DOI 10.14744/hnhj.2026.82997 Frei zugänglicher VolltextQuelle: OpenAlex

  7. KRAS Mutasyonu Saptanmayan Metastatik Kolorektal Kanserli Hastalarda Anti-EGFR Kullanımı-Ulusal Onco-Colon Çalışması Gerçek Yaşam Verleri

    DergiPark (Istanbul University), 2025

    Quelle: OpenAlex

  8. The impact of carboplatin on pathologic complete response and survival based on HER2 low and HER2 zero status in triple negative breast cancer patients receiving neoadjuvant chemotherapy: a multicenter real-world analysis

    BMC Cancer, 2025

    DOI 10.1186/s12885-025-14252-3 PMID 40329228 3 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  9. Evaluating the Effectiveness of Cyclin-Dependent Kinase 4/6 Inhibitors in Early- and Very Early-Onset Metastatic Breast Cancer: A Multicenter Study

    Medicina, 2025

    DOI 10.3390/medicina61010154 PMID 39859134 2 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

  10. Real-world treatment outcomes from nationwide Onco-colon Turkey registry in RAS wild-type patients treated with biologics second-line mCRC

    Journal of Oncology Pharmacy Practice, 2024

    DOI 10.1177/10781552241241004 PMID 38613329 Frei zugänglicher VolltextQuelle: OpenAlex

  11. The role of laboratory indices on treatment response and survival in breast cancer receiving neoadjuvant chemotherapy

    Scientific Reports, 2024

    DOI 10.1038/s41598-024-63096-7 PMID 38802494 21 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  12. Prognostic Impact and Clinical Features of Spread through Air Spaces in Operated Lung Cancer: Real-World Analysis

    Medicina, 2024

    DOI 10.3390/medicina60081374 PMID 39202654 10 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  13. Neoadjuvant Chemotherapy and Pathologic Complete Response in HR+/HER2− Breast Cancer: Impact of Tumor Ki67 and ER Status

    Chemotherapy, 2024

    DOI 10.1159/000537874 PMID 38368871 5 Zitationen (Europe PMC) Quelle: OpenAlex

  14. A Novel Prognostic Indicator for Immunotherapy Response: Lymphocyte-to-Albumin (LA) Ratio Predicts Survival in Metastatic NSCLC Patients

    Cancers, 2024

    DOI 10.3390/cancers16142512 PMID 39061152 5 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  15. Evaluating the Effectiveness of Nivolumab in Metastatic Lung Cancer Among Patients Aged 65 and Older

    Journal of Clinical Medicine, 2024

    DOI 10.3390/jcm13206263 PMID 39458213 2 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  16. Does Adjuvant Chemotherapy Benefit Patients with T4 N0 Colon Cancer?

    Medicina, 2024

    DOI 10.3390/medicina60081372 PMID 39202652 3 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  17. Exploring the Clinical Impact of RANK Pathway Inhibition in Advanced Breast Cancer: Insights From a Retrospective Study on CDK4/6 Inhibitors and Antiresorptive Therapy

    Cureus, 2024

    DOI 10.7759/cureus.63362 PMID 39070363 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  18. Combining Endocrine Therapy with Trastuzumab Emtansine Improves Progression-Free Survival and Overall Survival in HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer

    Medicina, 2024

    DOI 10.3390/medicina60060951 PMID 38929568 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  19. Prognostic scores in pulmonary large cell neuroendocrine carcinoma: A retrospective cohort study

    Heliyon, 2024

    DOI 10.1016/j.heliyon.2024.e25029 PMID 38317875 3 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  20. Efficacy and Safety of Ixabepilone in Metastatic Breast Cancer After Multiple Treatments: Analysis Based on Real-World Data

    Journal of Oncological Sciences, 2024

    DOI 10.37047/jos.2024-102164 1 Zitation (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

  21. Evaluating the Effectiveness of Nivolumab in Metastatic Lung Cancer Among Patients Aged 65 and Older

    2024

    DOI 10.20944/preprints202409.0812.v1 Frei zugänglicher VolltextQuelle: ORCID

  22. Evaluation of emergency department visits and immune-related adverse effects (irAEs) in patients treated with nivolumab

    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2024

    DOI 10.1007/s00520-024-08856-x PMID 39251491 Frei zugänglicher VolltextQuelle: Europe PMC

  23. Malignancies in individuals living with HIV/AIDS

    Romanian Journal of Infectious Diseases, 2024

    DOI 10.37897/rjid.2024.1.10 Frei zugänglicher VolltextQuelle: OpenAlex

  24. Are the results of clinical trials in patients with NSCLC reflected in real life? The Registurk-Lung study.

    Journal of Clinical Oncology, 2024

    DOI 10.1200/jco.2024.42.16_suppl.e20512 Frei zugänglicher VolltextQuelle: OpenAlex

  25. Are the results of clinical trials in patients with NSCLC reflected in real life? The Registurk-Lung study

    Bursa Uludag University - AVESIS, 2024

    Quelle: OpenAlex

  26. Evaluation of the effectiveness of colorectal cancer screening intervention

    Cancer Causes & Control, 2024

    DOI 10.1007/s10552-023-01839-z PMID 38172469 Quelle: OpenAlex

  27. Outcomes of surveillance versus adjuvant treatment for patients with stage-I seminoma: a single-center experience

    World journal of urology, 2023

    DOI 10.1007/s00345-023-04482-0 PMID 37351618 3 Zitationen (Europe PMC) Quelle: Europe PMC

  28. Does Proton Pump Inhibitors Decrease the Efficacy of Palbociclib and Ribociclib in Patients with Metastatic Breast Cancer?

    Medicina Lithuania, 2023

    DOI 10.3390/medicina59030557 PMID 36984558 12 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

  29. Retrospective Evaluation of the Efficacy of Gemcitabine-Based Therapies After FOLFIRINOX Failure in Advanced Pancreatic Cancer, Multi-Center Real-Life Data

    Pancreas, 2023

    DOI 10.1097/mpa.0000000000002238 PMID 37816170 2 Zitationen (Europe PMC) Quelle: ORCID

  30. The association of hemoglobin/red blood distribution width with overall survival: a retrospective analysis of melanoma

    Esperienze Dermatologiche, 2023

    DOI 10.23736/s1128-9155.23.00556-3 1 Zitation (OpenAlex) Quelle: OpenAlex

  31. The Prognostic Utility of the Metastatic Lymph Node Ratio and the Number of Regional Lymph Nodes Removed from Patients with Small Bowel Adenocarcinomas

    Medicina, 2023

    DOI 10.3390/medicina59081472 PMID 37629761 4 Zitationen (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

  32. Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer

    Journal of Cancer Research and Therapeutics, 2022

    DOI 10.4103/jcrt.jcrt_1104_21 PMID 36510987 6 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  33. Real-world treatment outcomes from nationwide Onco-colon Turkey registry in RAS wild-type patients treated with biologics second-line mCRC.

    Journal of Clinical Oncology, 2022

    DOI 10.1200/jco.2022.40.16_suppl.e15562 Quelle: OpenAlex

  34. The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study

    Anti-Cancer Drugs, 2022

    DOI 10.1097/cad.0000000000001310 PMID 35703239 3 Zitationen (Europe PMC) Quelle: OpenAlex

  35. Factors affecting the mortality rate of patients with cancer hospitalized with COVID-19: a single center’s experience

    Journal of Chemotherapy, 2021

    DOI 10.1080/1120009x.2021.1923153 PMID 34032198 6 Zitationen (Europe PMC) Quelle: OpenAlex

  36. Does systemic anti-tumor therapy increase COVID-19 risk in patients with cancer?

    Journal of Oncology Pharmacy Practice, 2021

    DOI 10.1177/10781552211015762 PMID 33961521 10 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  37. Real-world treatment outcomes from nationwide ONCO-colon Turkey registry in RAS wild-type patients treated with biologics first-line metastatic colorectal cancer.

    Journal of Clinical Oncology, 2021

    DOI 10.1200/jco.2021.39.15_suppl.e15561 Quelle: OpenAlex

  38. Prognostic factors of ado-trastuzumab emtansine treatment in patients with metastatic HER-2 positive breast cancer

    Journal of Oncology Pharmacy Practice, 2021

    DOI 10.1177/1078155220924088 PMID 32423326 8 Zitationen (Europe PMC) Quelle: ORCID

  39. Efficacy of abiraterone acetate in castration‐resistant metastatic prostate cancer: A real‐world data analysis

    Asia-Pacific Journal of Clinical Oncology, 2021

    DOI 10.1111/ajco.13426 PMID 32892496 4 Zitationen (Europe PMC) Quelle: ORCID

  40. Is the duration of castration resistance predictive for sequential treatment responses in the metastatic castration-resistant prostate cancer setting?

    Journal of Oncology Pharmacy Practice, 2021

    DOI 10.1177/1078155220951612 PMID 32847482 2 Zitationen (Europe PMC) Quelle: ORCID

  41. Initial Ca 125 Value as a Predictive Marker for High-grade Serous Ovarian Cancer

    Journal of the College of Physicians and Surgeons Pakistan, 2021

    DOI 10.29271/jcpsp.2021.06.651 PMID 34102775 8 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

  42. Monoklonal Antikor VEGF Blokajı Yapan Ajanlar (Bevasizumab,Aflibercept, Ramicirumab)

    Turkiye Klinikleri Medical Oncology - Special Topics, 2021

    Quelle: OpenAlex

  43. Does the efficacy of regorafenib differ in chemotherapy refractory metastatic colorectal cancer patients who had mucinous pathology compared to those who had non-mucinous pathology?

    Current Problems in Cancer, 2020

    DOI 10.1016/j.currproblcancer.2020.100670 PMID 33129567 1 Zitation (Europe PMC) Quelle: OpenAlex

  44. PROGNOSTIC AND PREDICTIVE MARKERS OF FOLFIRI/AFLIBERCEPT IN PATIENTS WITH METASTATIC COLORECTAL CANCER (TOG STUDY)

    AYBU AVESIS, 2020

    Quelle: OpenAlex

  45. The value of plasma netrin-1 in non-small cell lung cancer patients as diagnostic and prognostic biomarker

    Tumor Biology, 2016

    DOI 10.1007/s13277-016-5025-y PMID 27067437 20 Zitationen (OpenAlex) Quelle: OpenAlex

  46. Cytoreductive surgery for intestinal cancer patients metastatic to the adnexal presenting as primary ovarian cancer.

    Journal of Clinical Oncology, 2015

    DOI 10.1200/jco.2015.33.15_suppl.e14651 Quelle: OpenAlex

  47. Akciğer kanserinde sağkalımı etkileyen klinikopatolojik özellikler

    Marmara medical journal, 2015

    DOI 10.5472/mmj.2015.03731.1 2 Zitationen (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

  48. Akciğer kanserinde sağkalımı etkileyen klinikopatolojik özellikler

    Kocaeli Üniversitesi - AVESİS, 2015

    DOI 10.5472/mmj.2015.03829.1 Quelle: OpenAlex

  49. Netrin-1 concentrations in patients with advanced gastric cancer and its relation with treatment

    Biomarkers, 2012

    DOI 10.3109/1354750x.2012.709882 PMID 22889408 17 Zitationen (Europe PMC) Quelle: OpenAlex

  50. Eight-cycle rituximab therapy resulted in complete remission in primary cutaneous marginal zone lymphoma

    Leukemia Research, 2010

    DOI 10.1016/j.leukres.2010.02.013 PMID 20219245 5 Zitationen (Europe PMC) Quelle: OpenAlex